An observational study in Gestational Diabetes Mellitus (GDM) and Lactating Mother, sponsored by Prof. Dr. Cemil Tascıoglu Education and Research Hospital Organization. Recruiting at 2 sites in Turkey (Türkiye). Open to female participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-03.
Sponsored by Prof. Dr. Cemil Tascıoglu Education and Research Hospital Organization · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 52 studies in Diabetes, Gestational with a site in Turkey — 9 open to participants now, 12 under way, none of them phase 3. Diabetes, Gestational · Turkey.
Among the 52 studies in Diabetes, Gestational with a site in Turkey, this one is the 8th largest by planned enrollment of the 24 observational ones that give a count, is one of 3 that started in 2026, is one of 24 observational ones, reaches primary completion later than 10 of the 11 other live ones, and was the 49th registered.
878 studies on the registry are indexed under Diabetes, Gestational; 196 are open to participants now.
Browse Diabetes, Gestational studies →9 of the 52 studies in Diabetes, Gestational with a site in Turkey are open now. Recruiting first, the newest first:
Burak Deniz Aydoğdu · Sites in Turkey
Ages 18–50 · Women only
Izmir Ataturk Training and Research Hospital · Sites in Turkey
Ages 18–45 · Women only · Healthy volunteers
Izmir Katip Celebi University · Sites in Turkey
Ages 18+ · Women only
Umraniye Education and Research Hospital · Sites in Turkey
Ages 18–39 · Women only
Ankara City Hospital Bilkent · Sites in Turkey
Ages 18–45 · Women only · Healthy volunteers
A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →
Of the 132 Diabetes, Gestational studies recruiting now, 60 (45%) set no upper age limit and 70 (53%) stop at 75 or younger; 12 take children under 18; 60 take healthy volunteers.
This study: 18 Years to 50 Years · female · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
52 studies; the count open now beside each. This study's row is marked.
First in 2013; this study’s year is marked. 3 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 140 is below the median of 175 across 290 observational studies indexed under Diabetes, Gestational.
Median enrollment 85 across the 28 interventional studies, 100 across the 24 observational. Of the 37 that completed or were terminated, 2 (5%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 52 has an industry lead sponsor. The 10 most frequent:
Prof. Dr. Cemil Tascıoglu Education and Research Hospital Organization is the lead sponsor of 87 studies on the registry; 15 are open to participants now.
Prof. Dr. Cemil Tascıoglu Education and Research Hospital Organization has 1 study filed under Diabetes, Gestational — fewer than ten, so there is no comparison to draw.
2 of the studies in Diabetes, Gestational with a site in Turkey that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07750431Samsun UniversityThe Role of Progesterone Membrane Receptors in the Development of Gestational Diabetes Mellitus | 2027-01-01 |
| NCT07067411Yeditepe UniversityGamified Education for Diabetes Self-Management in GDM | 2027-07-01 |
Add all 2 to your calendar (.ics) → With an account.
Among the 52 studies in Diabetes, Gestational with a site in Turkey, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Gestational diabetes mellitus (GDM) is a common metabolic disorder of pregnancy associated with increased maternal and fetal morbidity. Lactation has been suggested to improve maternal glucose metabolism, enhance insulin sensitivity, and reduce the risk of future glucose intolerance. However, evidence regarding the protective effect of lactation on the development of GDM in subsequent pregnancies remains limited.
This prospective observational cohort study aims to evaluate the association between lactation and the risk of gestational diabetes mellitus and related pregnancy complications in women who conceive during the lactation period. Routine glycemic markers including fasting plasma glucose, HbA1c, glycosuria, and 75-g oral glucose tolerance test (OGTT) results will be recorded. Ultrasonographic findings including fetal abdominal circumference percentile, estimated fetal weight percentile, and amniotic fluid index will also be assessed. The study will investigate whether lactation is associated with a reduced risk of GDM, fetal macrosomia, and polyhydramnios in subsequent pregnancies.
Gestational diabetes mellitus (GDM) is one of the most common metabolic complications of pregnancy and is associated with adverse maternal and neonatal outcomes, including fetal macrosomia, polyhydramnios, cesarean delivery, and future development of type 2 diabetes mellitus. Early identification of women at increased risk of GDM is essential for optimizing antenatal care and improving pregnancy outcomes.
Lactation has been reported to exert beneficial metabolic effects through increased glucose utilization, improved insulin sensitivity, and facilitation of postpartum weight loss. Previous studies have suggested that breastfeeding may reduce the long-term risk of type 2 diabetes in women with a history of GDM. However, evidence regarding the protective effect of lactation on the occurrence of gestational diabetes mellitus in subsequent pregnancies remains limited.
The present prospective observational cohort study aims to evaluate the relationship between lactation and the development of gestational diabetes mellitus in women who become pregnant during the lactation period. Pregnant women aged 18-50 years with singleton pregnancies who attend the participating obstetrics and gynecology clinics will be enrolled. Routine laboratory parameters obtained during antenatal care, including fasting plasma glucose, HbA1c, glycosuria, and 75-g oral glucose tolerance test (OGTT) results, will be recorded.
In addition, routine ultrasonographic measurements, including fetal abdominal circumference percentile (AC), estimated fetal weight percentile (EFW), and amniotic fluid index (AFI), will be collected during the second and third trimesters. Maternal demographic and obstetric characteristics, including age, gravidity, parity, abortion history, and educational status, will also be documented.
The primary objective of the study is to determine whether lactation is associated with a reduced risk of gestational diabetes mellitus. Secondary objectives include evaluating the association between lactation and pregnancy complications related to altered glucose metabolism, including fetal macrosomia and polyhydramnios. The findings of this study may contribute to a better understanding of the metabolic effects of lactation and provide evidence for strategies aimed at reducing the burden of gestational diabetes mellitus in future pregnancy.
Pregnant individuals aged 18-50 years who conceived during the lactation period and are receiving antenatal care at participating obstetrics and gynecology clinics. Participants must have singleton pregnancies and available routine glycemic and ultrasonographic follow-up data. The study population represents women undergoing standard prenatal care in a tertiary care and secondary care hospital setting.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Singleton pregnant women aged 18-50 years who conceived during the lactation period and were followed at participating obstetrics and gynecology clinics.
Incidence of Gestational Diabetes Mellitus
Occurrence of gestational diabetes mellitus diagnosed by the 75-g oral glucose tolerance test performed between 24 and 28 weeks of gestation.
Time frame: 24-28 weeks of gestation
Fetal Macrosomia
Presence of fetal macrosomia assessed according to routine obstetric ultrasonographic evaluation and/or birth weight.
Time frame: From second trimester until delivery
Polyhydramnios
Development of polyhydramnios determined by routine ultrasonographic assessment of amniotic fluid volume during pregnancy.
Time frame: From second trimester until delivery
Plan to share: No — Individual participant data (IPD) will not be shared because the study involves patient-level clinical data collected from routine medical records. Data sharing is not included in the current study protocol or ethics committee application, and participant confidentiality and institutional data protection policies will be maintained.
No publications or documents are linked to this record.
Started Jan 2026 (actual). Primary completion is estimated for Dec 2027, 23 months after the start.
Of 142 non-industry observational studies under Diabetes, Gestational, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 70. This study's planned 23 months is below that.
Counting every sponsor, half of 144 studies reached it within 43 months; a quarter within 19 and three quarters within 73.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Prof. Dr. Cemil Tascıoglu Education and Research Hospital Organization